http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105663099-B

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-122
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06
filingDate 2016-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2019-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2019-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-105663099-B
titleOfInvention Purposes of the aloe-emodin in preparation reducing blood lipid and liver lipid lowering drug
abstract The invention discloses purposes of the aloe-emodin in preparation reducing blood lipid and liver lipid lowering drug, belong to pharmaceutical technology field.Wherein, the blood lipid refers to that total cholesterol and low-density lipoprotein in serum, liver rouge refer to the total cholesterol in liver.Toxicity test shows aloe-emodin without obvious toxic-side effects.The effect experiment of aloe-emodin shows that it can significantly reduce the total cholesterol and low-density lipoprotein in hyperlipemia animal model serum, has apparent effect for reducing blood fat;Aloe-emodin can also significantly reduce the content of total cholesterol in hyperlipemia animal model liver simultaneously, have apparent liver lipid lowering effect.Therefore, the invention proposes aloe-emodins to reduce the purposes in blood lipid and liver rouge, and effect for reducing fat is significant, toxicity is low, nonirritant, and price is low, it is easy to produce, transport, store and take, will have broad application prospects as the drug of reducing blood lipid and liver lipid lowering.
priorityDate 2016-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5997
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419477623
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ9Y4Z0
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6842
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP01295
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ9PS30
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60823
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419534626
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID137220
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID39042
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID137220
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3220
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID445580
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP24393
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419527388
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP31886
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10207
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ8R1I2
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID119260
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP63152
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP07492
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP63153
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ863C3
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419496926
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID518696
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419507953
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID450281383
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP08989
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419487501
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID119260
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID221493
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419491773
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID150311
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411029818
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419494496
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP47851
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP09472

Total number of triples: 49.